Scientific Programme​

The Conference brings together scientists and clinicians from a wide range of disciplines and from across the globe to gain a better understanding of the growing skeleton in health and disease. The scope ranges from basic molecular mechanisms to clinical aspects, from bone physiopathology to treatment.  Attendees have an interest in rare and inherited bone disorders, general aspects of bone metabolism and bone mass in children, adolescents and young adults.

Below you will find a useful overview of the four day conference programme.  Also, by clicking on the second button you can access a more detailed, interactive programme which has been updated regularly and has the talk summaries, where available, and oral communication abstracts linked. 

You can find the biographies for our our invited speakers HERE   

 

Key topics include

  • Bone cells
  • Bone quality
  • Bone tumours and other focal leisions
  • Nutrition and bone health
  • Rare bone diseases
  • Primary and secondary osteoporosis
  • Therapies – current and future management of paediatric bone disease

Continuing Medical Education (CME)

The application for CME credits by the European Accreditation Council for Continuing Medical Education (EACCME) is in process and more information about this will be uploaded in due course.

CME certificates will be sent electronically after the event to those who require them, on completion of a CME evaluation form (a link will be sent to all delegates at the end of the conference).

Who attends our conference?

  • Clinical Researchers
  • Basic Scientists
  • Paediatricians
  • Endocrinologists
  • Rheumatologists
  • Nephrologists
  • Haematologists
  • Gastroenterologists
  • Neurologists
  • Oncologists
  • Orthopaedic Surgeons
  • Urologists
  • Nutritionists
  • Industry Representatives
  • Nurses
  • Physiotherapists
  • Radiologists

Learning objectives

On completion of the meeting programme, the participant will have an enhanced understanding of a contemporary approach to clinical and basic paediatric bone science as related to:

  • Inherited and acquired bone disorders
  • Effects of chronic illness on muscle and bone
  • Bone therapeutics
  • Bone diagnostics
  • Bone signalling and metabolism

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.